V-ATPase inhibitors and implication in cancer treatment

Cancer Treatment Reviews

Volumn 35, Issue 8, 2009, Pages 707-713

  Pérez Sayáns, Mario ^a   Somoza Martín, José Manuel ^a   Barros Angueira, Francisco ^b   Rey, José Manuel Gándara ^a   García García, Abel ^a  

^a Entrerríos s/n ^*  (Spain)

^b Instituto de Salud Carlos III   (Spain)

Author keywords

Archazolid; Bafilomycin; Chemoresistance; Concanamycin; Indolyls; Salicylihalamide; Tumor cell growth; Tumor metastasis; V ATPase inhibitors; V ATPases

Indexed keywords

APICULAREN A; ARCHAZOLID A; ARCHAZOLID B; BAFILOMYCIN; BAFILOMYCIN A1; BROMOPYRUVIC ACID; CASPASE 3; CHONDROPSIN; CISPLATIN; CONCANAMYCIN A; CRUENTAREN; CYTOCHROME C; DESTRUXIN; DIPROPHYLLINE; FR 167356; FR 177995; FR 202126; INDOLE DERIVATIVE; LOBATAMIDE A; NIK 12192; OXIMIDINE I; PRODIGIOSIN; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE INHIBITOR; SALICYLIHAMIDE; SB 242784; TRIBUTYLTIN CHLORIDE; UNCLASSIFIED DRUG;

ACIDITY; ANTINEOPLASTIC ACTIVITY; CANCER CELL; CANCER CELL CULTURE; CELL DESTRUCTION; CELL PH; CELL PROLIFERATION; CELL SURVIVAL; CYTOTOXICITY; DRUG POTENTIATION; DRUG RESEARCH; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVATION; ENZYME INDUCTION; ENZYME INHIBITION; EXTRACELLULAR MATRIX; HUMAN; INHIBITION KINETICS; MALIGNANT NEOPLASTIC DISEASE; METASTASIS INHIBITION; METASTASIS POTENTIAL; MICROENVIRONMENT; NONHUMAN; PHENOTYPE; PROTON TRANSPORT; REVIEW; TISSUE INJURY; TUMOR CELL; TUMOR GROWTH;

ANIMALS; ANTINEOPLASTIC AGENTS; BICYCLO COMPOUNDS, HETEROCYCLIC; CELL SURVIVAL; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; HUMANS; MACROLIDES; VACUOLAR PROTON-TRANSLOCATING ATPASES;

EID: 70450284314     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2009.08.003     Document Type: Review

References (107)

1. Forgac M. Structure, function and regulation of the vacuolar (H+)-ATPases. FEBS Lett 440 3 (1998) 258-263
2. Nishi T., and Forgac M. The vacuolar (H+)-ATPases - nature's most versatile proton pumps. Nat Rev Mol Cell Biol 3 2 (2002) 94-103
3. Kawasaki-Nishi S., Nishi T., and Forgac M. Proton translocation driven by ATP hydrolysis in V-ATPases. FEBS Lett 545 1 (2003) 76-85
4. Finbow M.E., and Harrison M.A. The vacuolar H+ATPase: a universal proton pump of eukaryotes. Biochem J 324 Pt 3 (1997) 697-712
5. Kane P.M. Introduction: V-ATPases. J Bioenerg Biomembr 1 3-5 (1999) 1992-1998
6. Stevens T.H., and Forgac M. Structure, function and regulation of the vacuolar (H+)-ATPase. Annu Rev Cell Dev Biol 13 (1997) 779-808
7. Moriyama Y., and Nelson N. H+translocating ATPase in Golgi apparatus. Characterization as vacuolar H+ATPase and its subunit structures. J Biol Chem 264 31 (1989) 18445-18450
8. Schoonderwoert V.T.G., Holthuis J.C.M., Tanaka S., Tooze S.A., and Martens G.J.M. Inhibition of the vacuolar H+-ATPase perturbs the transport, sorting, processing and release of regulated secretory proteins. Eur J Biochem 267 17 (2000) 5646-5654
9. Martinez-Zaguilan R., Lynch R.M., Martinez G.M., and Gillies R.J. Vacuolar-type H(+)-ATPases are functionally expressed in plasma membranes of human tumor cells. Am J Physiol Cell Physiol 265 4 (1993) C1015-C1029
10. Fais S., De Milito A., You H., and Qin W. Targeting vacuolar H+ATPases as a new strategy against cancer. Cancer Res 67 22 (2007) 10627-10630
11. Bowman E.J., Siebers A., and Altendorf K. Bafilomycins: a class of inhibitors of membrane ATPases from microorganisms, animal cells, and plant cells. Proc Natl Acad Sci USA 85 21 (1988) 7972-7976
12. Moriyama Y., and Nelson N. Inhibition of vacuolar H+ATPases by fusidic acid and suramin. FEBS Lett 234 2 (1988) 383-386
13. Erickson K.L., Beutler J.A., Cardellina II J.H., and Boyd M.R. Salicylihalamides A and B, novel cytotoxic macrolides from the marine sponge Haliclona sp. J Org Chem 62 23 (1997) 8188-8192
14. Galinis D.L., McKee T.C., Pannell L.K., Cardellina J.H., and Boyd M.R. Lobatamides A and B, novel cytotoxic macrolides from the Tunicate Aplidium lobatum. J Org Chem 62 26 (1997) 8968-8969
15. Kunze B., Janse R., Sasse F., Höfle G., and Reichenbach H. Apicularens A and B, New cytostatic macrolides from Chondromyces species (Myxobacteria): production, physico-chemical and biological properties. J Antibiot Tokyo 51 12 (1998) 1075-1080
16. Gagliardi S., Nadler G., Consolandi E., Parini C., Morvan M., Legave M.N., et al. 4-Pentadienamides: novel and selective inhibitors of the vacuolar H+ATPase of osteoclasts with bone antiresorptive activity. J Med Chem 41 10 (1998) 1568-1573
17. Nadler G., Morvan M., Delimoge I., Belfiore P., Zocchetti A., James I., et al. (2Z,4E)-5-(5,6-dichloro-2-indolyl)-2-methoxy-N-(1,2,2,6,6-pentamethylpip eridin-4-yl)-2,4-pentadienamide, a novel, potent and selective inhibitor of the osteoclast V-ATPase. Bioorg Med Chem Lett 8 24 (1998) 3621-3626
18. Kim J.W., Shin-Ya K., Furihata K., Hayakawa Y., and Seto H. Oximidines I and II: novel antitumor macrolides from Pseudomonas sp. J Org Chem 64 1 (1999) 153-155
19. Sasse F., Steinmetz H., Hofle G., and Reichenbach H. Archazolids, new cytotoxic macrolactones from Archangium gephyra (Myxobacteria). Production, isolation, physico-chemical and biological properties. J Antibiot Tokyo 56 6 (2003) 520-525
20. Shen R., Lin C.T., Bowman E.J., Bowman B.J., and Porco Jr. J.A. Lobatamide C: total synthesis, stereochemical assignment, preparation of simplified analogues, and V-ATPase inhibition studies. J Am Chem Soc 125 26 (2003) 7889-7901
21. Kunze B., Steinmetz H., Hofle G., Huss M., Wieczorek H., and Reichenbach H. Cruentaren, a new antifungal salicylate-type macrolide from Byssovorax cruenta (myxobacteria) with inhibitory effect on mitochondrial ATPase activity. Fermentation and biological properties. J Antibiot (Tokyo) 59 10 (2006) 664-668
22. Petrangolini G., Supino R., Pratesi G., Bo L.D., Tortoreto M., Croce A.C., et al. Effect of a novel vacuolar-H+ATPase inhibitor on cell and tumor response to camptothecins. J Pharmacol Exp Ther 318 3 (2006) 939-946
23. Saroussi S., and Nelson N. Vacuolar H(+)-ATPase-an enzyme for all seasons. Pflugers Arch (2008)
24. Niikura K. Effect of a V-ATPase inhibitor, FR202126, in syngeneic mouse model of experimental bone metastasis. Cancer Chemother Pharmacol 60 4 (2007) 555-562
25. Hesselink R.W., Fedorov A., Hemminga M.A., and Prieto M. Membrane-bound peptides from V-ATPase subunit a do not interact with an indole-type inhibitor. J Pept Sci 14 4 (2008) 383-388
26. Forgac M. Structure and function of vacuolar class of ATP-driven proton pumps. Physiol Rev 69 3 (1989) 765-796
27. Finbow M.E., Eliopoulos E.E., Jackson P.J., Keen J.N., Meagher L., Thompson P., et al. Protein Eng 1 (1992) 7-15
28. Zhang K., Wang Z.Q., and Gluck S. Identification and partial purification of a cytosolic activator of vacuolar H(+)-ATPases from mammalian kidney. J Biol Chem 267 14 (1992) 9701-9705
29. Zhang K., Wang Z.Q., and Gluck S.. A cytosolic inhibitor of vacuolar H(+)-ATPases from mammalian kidney. J Biol Chem 267 21 (1992) 14539-14542
30. Drose S., and Altendorf K. Bafilomycins and concanamycins as inhibitors of V-ATPases and P-ATPases. J Exp Biol 200 Pt 1 (1997) 1-8
31. Muroi M., Shiragami N., and Takatsuki A. Destruxin B, a specific and readily reversible inhibitor of vacuolar-type H(+)-translocating ATPase. Biochem Biophys Res Commun 205 2 (1994) 1358-1365
32. Kataoka T., Muroi M., Ohkuma S., Waritani T., Magae J., Takatsuki A., et al. Prodigiosin 25-C uncouples vacuolar type H(+)-ATPase, inhibits vacuolar acidification and affects glycoprotein processing. FEBS Lett 359 1 (1995) 53-59
33. Cantrell C.L., Gustafson K.R., Cecere M.R., Pannell L.K., and Boyd M.R. Chondropsins A and B: novel tumor cell growth-inhibitory macrolide lactams from the marine sponge Chondropsis sp. J Am Chem Soc 122 37 (2000) 8825-8829
34. Sorensen M.G., Henriksen K., Neutzsky-Wulff A.V., Dziegiel M.H., and Karsdal M.A. Diphyllin, a novel and naturally potent V-ATPase inhibitor, abrogates acidification of the osteoclastic resorption lacunae and bone resorption. J Bone Miner Res 22 10 (2007) 1640-1648
35. Zhang J., Feng Y., and Forgac M. Proton conduction and bafilomycin binding by the V0 domain of the coated vesicle V-ATPase. J Biol Chem 269 38 (1994) 23518-23523
36. Bowman B.J., and Bowman E.J. Mutations in subunit C of the vacuolar ATPase confer resistance to bafilomycin and identify a conserved antibiotic binding site. J Biol Chem 277 6 (2002) 3965-3972
37. Huss M., Ingenhorst G., Konig S., Gassel M., Drose S., Zeeck A., et al. Concanamycin A, the specific inhibitor of V-ATPases, binds to the V(o) subunit c. J Biol Chem 277 43 (2002) 40544-40548
38. Fernandes F., Loura L.M., Fedorov A., Dixon N., Kee T.P., Prieto M., et al. Binding assays of inhibitors towards selected V-ATPase domains. Biochim Biophys Acta 1758 11 (2006) 1777-1786
39. Bowman B.J., McCall M.E., Baertsch R., and Bowman E.J. A model for the proteolipid ring and bafilomycin/concanamycin-binding site in the vacuolar ATPase of Neurospora crassa. J Biol Chem 281 42 (2006) 31885-31893
40. Murata T., Kawano M., Igarashi K., Yamato I., and Kakinuma Y. Catalytic properties of Na(+)-translocating V-ATPase in Enterococcus hirae. Biochim Biophys Acta 1505 1 (2001) 75-81
41. Bowman E.J., Graham L.A., Stevens T.H., and Bowman B.J. The bafilomycin/concanamycin binding site in subunit c of the V-ATPases from Neurospora crassa and Saccharomyces cerevisiae. J Biol Chem 279 32 (2004) 33131-33138
42. Bowman E.J., and Bowman B.J. Cellular role of the V-ATPase in Neurospora crassa: analysis of mutants resistant to concanamycin or lacking the catalytic subunit A. J Exp Biol 203 Pt 1 (2000) 97-106
43. Teplova V.V., Tonshin A.A., Grigoriev P.A., Saris N.E., and Salkinoja-Salonen M.S. Bafilomycin A1 is a potassium ionophore that impairs mitochondrial functions. J Bioenerg Biomembr 39 4 (2007) 321-329
44. Scheidt K.A., Bannister T.D., Tasaka A., Wendt M.D., Savall B.M., Fegley G.J., et al. Total synthesis of (-)-Bafilomycin A1. J Am Chem Soc 124 24 (2002) 6981-6990
45. Boyd M.R., Farina C., Belfiore P., Gagliardi S., Kim J.W., Hayakawa Y., et al. Discovery of a novel antitumor benzolactone enamide class that selectively inhibits mammalian vacuolar-type (H+)-atpases. J Pharmacol Exp Ther 297 1 (2001) 114-120
46. Bowman E.J., and Bowman B.J. V-ATPases as drug targets. J Bioenerg Biomembr 37 6 (2005) 431-435
47. Wu Y., Liao X., Wang R., Xie X.S., and De Brabander J.K. Total synthesis and initial structure-function analysis of the potent V-ATPase inhibitors salicylihalamide A and related compounds. J Am Chem Soc 124 13 (2002) 3245-3253
48. Sugimoto Y., Konoki K., Murata M., Matsushita M., Kanazawa H., and Oishi T. Design, synthesis, and biological evaluation of fluorinated analogues of salicylihalamide. J Med Chem 52 3 (2009) 798-806
49. Lebreton S., Jaunbergs J., Roth M.G., Ferguson D.A., and De Brabander J.K. Evaluating the potential of Vacuolar ATPase inhibitors as anticancer agents and multigram synthesis of the potent salicylihalamide analog saliphenylhalamide. Bioorg Med Chem Lett 18 22 (2008) 5879-5883
50. Huss M., Sasse F., Kunze B., Jansen R., Steinmetz H., Ingenhorst G., et al. Archazolid and apicularen: novel specific V-ATPase inhibitors. BMC Biochem 6 (2005) 13
51. Shen R., Lin C.T., Bowman E.J., Bowman B.J., and Porco Jr. J.A. Synthesis and V-ATPase inhibition of simplified lobatamide analogues. Org Lett 4 18 (2002) 3103-3106
52. Kunze B., Sasse F., Wieczorek H., Huss M., and Cruentaren A. A highly cytotoxic benzolactone from Myxobacteria is a novel selective inhibitor of mitochondrial F1-ATPases. FEBS Lett 581 18 (2007) 3523-3527
53. Menche D., Hassfeld J., Sasse F., Huss M., and Wieczorek H. Design, synthesis, and biological evaluation of novel analogues of archazolid: a highly potent simplified V-ATPase inhibitor. Bioorg Med Chem Lett 17 6 (2007) 1732-1735
54. Roethle P.A., Chen I.T., and D T. Total synthesis of (-)-archazolid B. J Am Chem Soc 129 29 (2007) 8960-8961
55. Hassfeld J., Fares C., Steinmetz H., Carlomagno T., and Menche D. Stereochemical determination of Archazolid A and B, highly potent vacuolar-type ATPase inhibitors from the Myxobacterium Archangium gephyra. Org Lett 8 21 (2006) 4751-4754
56. Dixon N., Pali T., Kee T.P., Ball S., Harrison M.A., Findlay J.B., et al. Interaction of spin-labeled inhibitors of the vacuolar H+ATPase with the transmembrane Vo-sector. Biophys J 94 2 (2008) 506-514
57. Pali T., Whyteside G., Dixon N., Kee T.P., Ball S., Harrison M.A., et al. Interaction of inhibitors of the vacuolar H(+)-ATPase with the transmembrane Vo-sector. Biochemistry 43 38 (2004) 12297-12305
58. Supino R., Petrangolini G., Pratesi G., Tortoreto M., Favini E., Bo L.D., et al. Antimetastatic effect of a small-molecule vacuolar H+ATPase inhibitor in in vitro and in vivo preclinical studies. J Pharmacol Exp Ther 324 1 (2008) 15-22
59. Dell'Antone P. Inactivation of H+vacuolar ATPase by the energy blocker 3-bromopyruvate a new antitumour agent. Life Sci 79 21 (2006) 2049-2055
60. Takeda M., Suno-Ikeda C., Shimabukuro K., Yoshida M., and Yokoyama K. Mechanism of inhibition of the V-type molecular motor by tributyltin chloride. Biophys J 96 3 (2009) 1210-1217
61. Niikura K., Nakajima S., Takano M., and Yamazaki H. FR177995, a novel vacuolar ATPase inhibitor, exerts not only an inhibitory effect on bone destruction but also anti-immunoinflammatory effects in adjuvant-induced arthritic rats. Bone 4 (2007) 888-894
62. Niikura K., Takano M., and Sawada M. A novel inhibitor of vacuolar ATPase, FR167356, which can discriminate between osteoclast vacuolar ATPase and lysosomal vacuolar ATPase. Br J Pharmacol 142 3 (2004) 558-566
63. McLean L.A., Roscoe J., Jorgensen N.K., Gorin F.A., and Cala P.M. Malignant gliomas display altered pH regulation by NHE1 compared with nontransformed astrocytes. Am J Physiol Cell Physiol 278 4 (2000) C676-C888
64. + exchanger in metastasis. Nat Rev Cancer 5 10 (2005) 786-795
65. Perona R., and Serrano R. Increased pH and tumorigenicity of fibroblasts expressing a yeast proton pump. Nature 334 6181 (1988) 438-440
66. Sennoune S.R., and Martinez-Zaguilan R. Plasmalemmal vacuolar H+ATPases in angiogenesis diabetes and cancer. J Bioenerg Biomembr 39 5-6 (2007) 427-433
67. Montcourrier P., Silver I., Farnoud R., Bird I., and Rochefort H. Breast cancer cells have a high capacity to acidify extracellular milieu by a dual mechanism. Clin Exp Metastasis 15 4 (1997) 382-392
68. Parkins C.S., Stratford M.R., Dennis M.F., Stubbs M., and Chaplin D.J. The relationship between extracellular lactate and tumour pH in a murine tumour model of ischaemia-reperfusion. Br J Cancer 75 3 (1997) 319-323
69. Martinez-Zaguilan R., Seftor E.A., Seftor R.E., Chu Y.W., Gillies R.J., and Hendrix M.J. Acidic pH enhances the invasive behavior of human melanoma cells. Clin Exp Metastasis 14 2 (1996) 176-186
70. Rofstad E.K., Mathiesen B., Kindem K., and Galappathi K. Acidic extracellular pH promotes experimental metastasis of human melanoma cells in athymic nude mice. Cancer Res 66 13 (2006) 6699-6707
71. Montcourrier P., Mangeat P.H., Valembois C., Salazar G., Sahuquet A., Duperray C., et al. Characterization of very acidic phagosomes in breast cancer cells and their association with invasion. J Cell Sci 107 Pt 9 (1994) 2381-2391
72. Rozhin J., Sameni M., Ziegler G., and Sloane B.F. Pericellular pH affects distribution and secretion of cathepsin B in malignant cells. Cancer Res 54 24 (1994) 6517-6525
73. Johnson L.L., Pavlovsky A.G., Johnson A.R., Janowicz J.A., Man C.F., Ortwine D.F., et al. A rationalization of the acidic pH dependence for stromelysin-1 (matrix metalloproteinase-3) catalysis and inhibition. J Biol Chem 275 15 (2000) 11026-11033
74. Kato Y., Lambert C.A., Colige A.C., Mineur P., Noel A., Frankenne F., et al. Acidic extracellular pH induces matrix metalloproteinase-9 expression in mouse metastatic melanoma cells through the phospholipase d-mitogen-activated protein kinase signaling. J Biol Chem 280 12 (2005) 10938-10944
75. Gocheva V., and Joyce J.A. Cysteine cathepsins and the cutting edge of cancer invasion. Cell Cycle 6 1 (2007) 60-64
76. Sennoune S.R., Bakunts K., Martinez G.M., Chua-Tuan J.L., Kebir Y., Attaya M.N., et al. Vacuolar H+ATPase in human breast cancer cells with distinct metastatic potential: distribution and functional activity. Am J Physiol Cell Physiol 286 6 (2004) C1443-C1452
77. Lu X., Qin W., Li J., Tan N., Pan D., Zhang H., et al. The Growth and Metastasis of Human Hepatocellular Carcinoma Xenografts Are Inhibited by Small Interfering RNA Targeting to the Subunit ATP6L of Proton Pump. Cancer Res 65 15 (2005) 6843-6849
78. Halaban R., Patton R.S., Cheng E., Svedine S., Trombetta E.S., Wahl M.L., et al. Abnormal acidification of melanoma cells induces tyrosinase retention in the early secretory pathway. J Biol Chem 277 17 (2002) 14821-14828
79. Nanda A., Brumell J.H., Nordstrom T., Kjeldsen L., Sengelov H., Borregaard N., et al. Activation of proton pumping in human neutrophils occurs by exocytosis of vesicles bearing vacuolar-type H+ATPases. J Biol Chem 271 27 (1996) 15963-15970
80. Gatenby R.A., and Gillies R.J. Why do cancers have high aerobic glycolysis?. Nat Rev Cancer 4 11 (2004) 891-899
81. Volk C., Albert T., and Kempski O.S. A proton-translocating H+ATPase is involved in C6 glial pH regulation. Biochim Biophys Acta 1372 1 (1998) 28-36
82. McSheehy P.M., Troy H., Kelland L.R., Judson I.R., Leach M.O., and Griffiths J.R. Increased tumour extracellular pH induced by Bafilomycin A1 inhibits tumour growth and mitosis in vivo and alters 5-fluorouracil pharmacokinetics. Eur J Cancer 39 4 (2003) 532-540
83. Zhong H., De Marzo A.M., Laughner E., Lim M., DA H., Zagzag D., et al. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res 59 22 (1999) 5830-5835
84. Lim J.H., Park J.W., Kim M.S., Park S.K., Johnson R.S., and Chun Y.S. Bafilomycin induces the p21-mediated growth inhibition of cancer cells under hypoxic conditions by expressing hypoxia-inducible factor-1alpha. Mol Pharmacol 70 6 (2006) 1856-1865
85. Ohta T., Arakawa H., Futagami F., Fushida S., Kitagawa H., Kayahara M., et al. Bafilomycin A1 induces apoptosis in the human pancreatic cancer cell line Capan-1. J Pathol 185 3 (1998) 324-330
86. Aiko K., Tsujisawa T., Koseki T., Hashimoto S., Morimoto Y., Amagasa T., et al. Involvement of cytochrome c and caspases in apoptotic cell death of human submandibular gland ductal cells induced by concanamycin A. Cell Signal 14 8 (2002) 717-722
87. De Milito A., Iessi E., Logozzi M., Lozupone F., Spada M., Marino M.L., et al. Proton pump inhibitors induce apoptosis of human B-cell tumors through a caspase-independent mechanism involving reactive oxygen species. Cancer Res 67 11 (2007) 5408-5417
88. Gottlieb R.A., Giesing H.A., Zhu J.Y., Engler R.L., and Babior B.M. Cell acidification in apoptosis: granulocyte colony-stimulating factor delays programmed cell death in neutrophils by up-regulating the vacuolar H(+)-ATPase. Proc Natl Acad Sci USA 92 13 (1995) 5965-5968
89. Xu J., Feng H.T., Wang C., Yip K.H., Pavlos N., Papadimitriou J.M., et al. Effects of Bafilomycin A1: an inhibitor of vacuolar H (+)-ATPases on endocytosis and apoptosis in RAW cells and RAW cell-derived osteoclasts. J Cell Biochem 88 6 (2003) 1256-1264
90. Morimura T., Fujita K., Akita M., Nagashima M., and Satomi A. The proton pump inhibitor inhibits cell growth and induces apoptosis in human hepatoblastoma. Pediatr Surg Int 24 10 (2008) 1087-1094
91. Nakashima S., Hiraku Y., Tada-Oikawa S., Hishita T., Gabazza E.C., and Tamaki S. et al. Vacuolar H+ATPase inhibitor induces apoptosis via lysosomal dysfunction in the human gastric cancer cell line MKN-1. J Biochem 134 3 (2003) 359-364
92. Hishita T., Tada-Oikawa S., Tohyama K., Miura Y., Nishihara T., Tohyama Y., et al. Caspase-3 activation by lysosomal enzymes in cytochrome c-independent apoptosis in myelodysplastic syndrome-derived cell line P39. Cancer Res 61 7 (2001) 2878-2884
93. Wu Y.C., Wu W.K.K., Li Y., Yu L., Li Z.J., Wong C.C.M., et al. Inhibition of macroautophagy by bafilomycin A1 lowers proliferation and induces apoptosis in colon cancer cells. Biochem Biophys Res Commun 382 2 (2009) 451-456
94. Meijer A.J., and Codogno P. Regulation and role of autophagy in mammalian cells. Int J Biochem Cell Biol 36 12 (2004) 2445-2462
95. Mortimore G.E., Hutson N.J., and Surmacz C.A. Quantitative correlation between proteolysis and macro- and microautophagy in mouse hepatocytes during starvation and refeeding. Proc Natl Acad Sci USA 80 8 (1983) 2179-2183
96. Martinez-Munoz G.A., and Kane P. Vacuolar and plasma membrane proton pumps collaborate to achieve cytosolic pH homeostasis in yeast. J Biol Chem 283 29 (2008) 20309-20319
97. Lyons J.C., Kim G.E., and Song C.W. Modification of intracellular pH and thermosensitivity. Radiat Res 129 1 (1992) 79-87
98. Hayashi Y., Katayama K., Togawa T., Kimura T., and Yamaguchi A. Effects of bafilomycin A1 a vacuolar type H+ ATPase inhibitor on the thermosensitivity of a human pancreatic cancer cell line. Int J Hyperthermia 22 4 (2006) 275-285
99. Ohta T., Arakawa H., Futagami F., Fushida S., Kitagawa H., Kayahara M., et al. A new strategy for the therapy of pancreatic cancer by proton pump inhibitor. Gan To Kagaku Ryoho 12 (1996) 1660-1664
100. Murakami T., Shibuya I., Ise T., Chen Z.S., Akiyama S., Nakagawa M., et al. Elevated expression of vacuolar proton pump genes and cellular PH in cisplatin resistance. Int J Cancer 93 6 (2001) 869-874
101. Torigoe T., Izumi H., Ise T., Murakami T., Uramoto H., Ishiguchi H., et al. Vacuolar H(+)-ATPase: functional mechanisms and potential as a target for cancer chemotherapy. Anticancer Drugs 3 (2002) 237-243
102. Torigoe T., Izumi H., Ishiguchi H., Uramoto H., Murakami T., Ise T., et al. Enhanced expression of the human vacuolar H+ATPase c subunit gene (ATP6L) in response to anticancer agents. J Biol Chem 277 39 (2002) 36534-36543
103. Sennoune S.R., Luo D., and Martinez-Zaguilan R. Plasmalemmal vacuolar-type H+ATPase in cancer biology. Cell Biochem Biophys 40 2 (2004) 185-206
104. Perez-Sayans M., Garcia-Garcia A., Reboiras-Lopez M.D., and Gandara-Vila P. Role of V-ATPases in solid tumors: Importance of the subunit C (Review). Int J Oncol 34 6 (2009) 1513-1520
105. Hinton A., Bond S., and Forgac M. V-ATPase functions in normal and disease processes. Pflugers Arch 457 3 (2009) 589-598
106. Hilgenbrink A.R., and Low P.S. Folate receptor-mediated drug targeting: from therapeutics to diagnostics. J Pharm Sci 94 10 (2005) 2135-2146
107. Huss M., and Wieczorek H. Inhibitors of V-ATPases: old and new players. J Exp Biol 212 Pt 3 (2009) 341-346